Evolent Health Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 results showed 9% sequential revenue growth and improved MER, driven by new launches and strong demand for oncology solutions. Guidance for 2026 was reiterated, with continued investment in AI and automation and two major new contracts expected to boost future revenue.
-
Smooth client implementations and conservative financial guidance set the stage for sequential EBITDA growth, with a strong pipeline and focus on risk-aligned products. Deleveraging and profitability are top priorities, while AI and clinical differentiation support long-term growth.
Fiscal Year 2025
-
Q4 2025 results exceeded guidance, with strong revenue and EBITDA growth driven by oncology and new contracts. 2026 guidance projects 30% revenue growth, margin expansion, and significant cost savings, despite exchange headwinds and conservative reserving for new business.
-
Specialty care management trends remain stable, with new contract protections and operational efficiencies supporting margin growth. Significant new business is expected to drive revenue and EBITDA improvements, while divestiture proceeds will be used to reduce debt and focus on core growth areas.
-
Q3 results exceeded expectations with strong revenue and EBITDA growth, driven by new contract wins and enhanced contract structures. 2026 revenue under contract is $2.5B, but EBITDA growth is uncertain due to potential membership declines in key markets.
-
EBITDA outperformance led to raised guidance, while revenue was adjusted due to contract timing. Major partnerships, robust pipeline, and AI-driven efficiencies support confidence in 2025 targets. Cash flow normalizes after one-time items, with a focus on deleveraging.
-
Q2 adjusted EBITDA exceeded expectations, with strong new business momentum and a robust pipeline, especially in Medicare Advantage. AI initiatives are driving efficiency, and 2026 revenue is projected to surpass $2.5 billion, despite exchange headwinds.
-
Despite recent market headwinds, demand and pipeline activity have surged, with a strong long-term growth outlook and a $150 billion addressable market. The company’s solutions improve care quality and reduce costs, with innovation in clinical support, provider alignment, and patient navigation driving both financial and clinical outcomes.
-
Q1 2025 results exceeded expectations, driven by strong organic growth, new contracts, and robust demand across all segments. Oncology cost trends were favorable, and the company reiterated its 2025 guidance, with significant liquidity and ongoing investments in AI and oncology navigation.
-
Performance Suite shifted to a capped risk model, balancing upside/downside for partners and aligning value creation with outcomes. AI-driven efficiency is expected to deliver $20M in annualized benefits by year-end, with more gains targeted. Business development is strong, and guidance reflects oncology trends and membership changes.
Fiscal Year 2024
-
2024 revenue grew 30% to $2.55B, with Adjusted EBITDA at $160.5M. 2025 guidance projects 15%-18% organic revenue growth and $135-$165M Adjusted EBITDA, supported by contract wins, margin improvements, and strong pipeline, despite ongoing oncology cost pressures.
-
Unexpected medical cost increases were driven by oncology utilization and delayed claims, prompting a shift to contracts with rate corridors or Tech Services to reduce risk. AI integration is set to boost efficiency, and strong demand persists across specialties. Clarity on key contracts is expected by February.
-
Specialty cost trends, especially in oncology, are accelerating due to scientific advances, higher cancer prevalence, and evolving therapies. The business is urgently seeking $100 million in revenue increases to offset these trends, focusing on contract adjustments, operational improvements, and AI-driven efficiencies, while maintaining growth in core specialties.
-
Q3 earnings fell short due to a $42M spike in medical costs, especially in oncology, prompting a downward revision of 2024 guidance. Despite this, record new business signings and strong cash flow highlight robust demand and long-term growth prospects.
-
The conference highlighted strong growth driven by specialty care management, successful integration of recent acquisitions, and the adoption of AI to boost efficiency. With a $150 billion TAM and robust demand from payers, the company remains on track for its $300 million EBITDA target.
-
Q2 revenue grew 37.9% year-over-year to $647.1 million, with adjusted EBITDA at $52 million. New rate increases and contracts are expected to drive margin and EBITDA growth in the second half, supporting confidence in the $300 million exit run rate target for 2024.
-
The session highlighted robust growth, high client retention, and a $150 billion market opportunity, with a focus on value-based specialty care and AI-driven efficiencies. Recent AI and M&A investments are expected to drive significant margin gains and expansion into new specialties.